BioCryst Pharmaceuticals
BCRX
134 hedge funds and large institutions have $245M invested in BioCryst Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 52 increasing their positions, 38 reducing their positions, and 25 closing their positions.
671% more call options, than puts
Call options by funds: $3.05M | Put options by funds: $396K
37% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 38
4% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 25
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less funds holding
Funds holding: 136 → 134 (-2)
9.59% less ownership
Funds ownership: 89.1% → 79.51% (-9.6%)
48% less capital invested
Capital invested by funds: $473M → $245M (-$228M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$9.64M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$8.28M |
| 3 |
EP
Eversept Partners
New York
|
+$7.26M |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
+$5.76M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$14.8M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$12.5M |
| 3 |
Millennium Management
New York
|
-$9.6M |
| 4 |
PVI
Pura Vida Investments
New York
|
-$7.52M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$7.09M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GTCM
151
Gyon Technologies Capital Management
Denville,
New Jersey
| – | -$41K | -11,851 | Closed |
|
|
PRC
152
Pearl River Capital
Niles,
Michigan
| – | -$38K | -10,989 | Closed |
|
|
QT
153
Quantamental Technologies
White Plains,
New York
| – | -$38K | -10,989 | Closed |
|
154
Group One Trading
Chicago,
Illinois
| – | -$15.3K | -5,558 | Closed |
|
155
Simplex Trading
Chicago,
Illinois
| – | -$7.99K | -2,903 | Closed |
|
156
1832 Asset Management
Toronto,
Ontario, Canada
| – | -$7K | -1,978 | Closed |
|
|
OC
157
Oakworth Capital
Birmingham,
Alabama
| – | -$138 | -50 | -50% |
|
|
LC
158
Lindbrook Capital
Calabasas,
California
| – | +$683 | +248 | New |
|
BCRX Hedge Fund Activity: Q1 2020 in Review
134 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q1 2020, worth a combined $245M — down 48% from $473M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new BCRX positions and 25 closed out — a net gain of 1 holder — while 52 added to existing stakes and 38 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $9.64M. The largest seller was Point72 Asset Management, cutting an estimated $14.8M.
- 134 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q1 2020, down from 136 in Q4 2019.
- Funds reported $245M of BioCryst Pharmaceuticals stock for Q1 2020, down 48% quarter-over-quarter.
- 26 funds opened new BioCryst Pharmaceuticals positions in Q1 2020 and 25 closed out, a net change of +1 holder.
- The largest BioCryst Pharmaceuticals buyer in Q1 2020 was Adage Capital Partners, an estimated $9.64M added.
- The largest BioCryst Pharmaceuticals seller in Q1 2020 was Point72 Asset Management, an estimated $14.8M sold.
Based on aggregated 13F filings for Q1 2020.